Replies to post #592938 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Again when was this 10-K filed? When was MIA approved? When did Dr. Bosch make the presentation in which the following figure was included? Has NWBO ever become the sponsor for NYAS? When was LP selected as ten women who make waves in life sciences world? When did Merck and Moderna PR their mediocre clinical results? When did rating agency downgrade NVCR? I can go on and on.

One thing for sure the shorts should plan their next step based on the analysis from the longs for their own benefits.

[jon_k84]

Two totally different scenarios, with very different language.

[dstock07734]

JC,

You definitely need to read this story about Merck acquiring Prometheus. It is a company with some good results from phase 2 trial for the type of diseases with market size tantamount to a peanut in comparison of oncology market. What message can we get from this news? Prometheus won the game in the house of cards. Another message is that all the BPs hit the sound barrier in immnotherapy. They don't have too much leverage to negotiate. Take Merck for example. The collaboration with Moderna brought nothing but a blow. When Merck made BMY withdraw from the combo trial, BMY didn't stop funding to the dendritic research. As a matter of fact, BMY continued funding Dr. Liau until the end of the research project ending the middle of last Summer. If BMY even intent to run against Merck in acquiring Prometheus, would BMY let NWBO owned by Merck without fight? What about Roche? In the ovarian cancer trial, Roche's drug was used.

But then on Dec. 7, 2022, everything changed for Prometheus. The company reported that PRA023 met the primary endpoint of two midphase trials in ulcerative colitis and Crohn’s disease. Prometheus’ stock went from $36 apiece to $103 at open on Dec. 8. The company moved to conduct a common stock offering that ultimately closed at $550 million, or $110 per share, on Dec. 13.

Then the board halted any remaining partnership talks. A virtual data room that had been opened during the due diligence process to provide a peek at Prometheus’ goods was shut down. Conversations continued with the previously interested parties, including Merck, culminating in meetings at J.P. Morgan with six parties. The parties said they were interested in a potential transaction, but none made an offer at that point. The virtual data room was restored.

Merck’s Sunil Patel, head of corporate development and licensing, told Prometheus CEO Mark McKenna in February that the pharma had “significant interest in a potential strategic transaction,” according to the SEC filing. In March, the big brass was brought in, with Merck CEO Rob Davis calling in an offer to acquire Prometheus for $150 per share with a closing target date of April 21. The offer was $50 per share less than where the deal would ultimately land.
Prometheus then turned to three other companies that had previously been engaged to gauge their level of interest in upping the ante. According to Bloomberg’s reporting, this included AbbVie and BMS, which both indicated a plan to submit an offer. The board informed Patel that Merck would have to “significantly increase” its bid.

Merck battled 2 other Big Pharmas to the end in pursuit of $11B Prometheus deal
https://www.fiercebiotech.com/biotech/merck-battled-2-other-big-pharmas-pursuit-11b-prometheus-deal

[hoffmann6383]

Nonsense. The warrant deal was finalized. This one in the recent 10q was not. Big difference.

On May 8, 2023, the Company received a $3.0 million prepayment for the purchase of securities for which the terms are in the process of being finalized.

Have a good one buddy!